CA3172349A1 - Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock - Google Patents
Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shockInfo
- Publication number
- CA3172349A1 CA3172349A1 CA3172349A CA3172349A CA3172349A1 CA 3172349 A1 CA3172349 A1 CA 3172349A1 CA 3172349 A CA3172349 A CA 3172349A CA 3172349 A CA3172349 A CA 3172349A CA 3172349 A1 CA3172349 A1 CA 3172349A1
- Authority
- CA
- Canada
- Prior art keywords
- shock
- adm
- therapy
- patient
- dpp3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159848 | 2020-02-27 | ||
| EP20159848.9 | 2020-02-27 | ||
| PCT/EP2021/054911 WO2021170838A1 (en) | 2020-02-27 | 2021-02-26 | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172349A1 true CA3172349A1 (en) | 2021-09-02 |
Family
ID=69742802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172349A Pending CA3172349A1 (en) | 2020-02-27 | 2021-02-26 | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230193348A1 (https=) |
| EP (1) | EP4111204A1 (https=) |
| JP (2) | JP2023516615A (https=) |
| CN (1) | CN115244401A (https=) |
| AU (1) | AU2021228207A1 (https=) |
| BR (1) | BR112022015215A2 (https=) |
| CA (1) | CA3172349A1 (https=) |
| MX (1) | MX2022010672A (https=) |
| WO (1) | WO2021170838A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010564A (es) * | 2020-02-27 | 2022-11-30 | Adrenomed Ag | Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque. |
| KR20250042158A (ko) | 2022-07-29 | 2025-03-26 | 아드레노메드 아게 | 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| CN119630969A (zh) | 2022-07-29 | 2025-03-14 | 4Teen4制药有限公司 | 预测患有败血症性休克的患者中的dpp3增加 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| AU2010332932B2 (en) | 2009-12-14 | 2013-01-17 | Navigo Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin |
| RU2569745C2 (ru) | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| PL2594588T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| SG11201402362VA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| DK2780371T3 (en) | 2011-11-16 | 2019-02-25 | Adrenomed Ag | ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE |
| EP4086283A1 (en) | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| AU2017252212B2 (en) * | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| SG11202002268XA (en) * | 2017-10-18 | 2020-04-29 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| MY202502A (en) * | 2017-10-25 | 2024-05-01 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
-
2021
- 2021-02-26 CN CN202180015815.5A patent/CN115244401A/zh active Pending
- 2021-02-26 US US17/802,799 patent/US20230193348A1/en active Pending
- 2021-02-26 CA CA3172349A patent/CA3172349A1/en active Pending
- 2021-02-26 MX MX2022010672A patent/MX2022010672A/es unknown
- 2021-02-26 EP EP21707707.2A patent/EP4111204A1/en active Pending
- 2021-02-26 BR BR112022015215A patent/BR112022015215A2/pt unknown
- 2021-02-26 WO PCT/EP2021/054911 patent/WO2021170838A1/en not_active Ceased
- 2021-02-26 AU AU2021228207A patent/AU2021228207A1/en active Pending
- 2021-02-26 JP JP2022551667A patent/JP2023516615A/ja active Pending
-
2025
- 2025-10-24 JP JP2025179567A patent/JP2026035582A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230193348A1 (en) | 2023-06-22 |
| CN115244401A (zh) | 2022-10-25 |
| MX2022010672A (es) | 2022-09-23 |
| JP2026035582A (ja) | 2026-03-04 |
| AU2021228207A1 (en) | 2022-10-20 |
| WO2021170838A1 (en) | 2021-09-02 |
| BR112022015215A2 (pt) | 2022-10-11 |
| EP4111204A1 (en) | 2023-01-04 |
| JP2023516615A (ja) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020338818B2 (en) | Therapy guidance and/or therapy monitoring for treatment of shock | |
| US20230193348A1 (en) | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock | |
| US20230104578A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock | |
| WO2020128039A2 (en) | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof | |
| US20260028423A1 (en) | Prediction of an increase of dpp3 in a patient with septic shock | |
| WO2024126793A1 (en) | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients | |
| RU2838370C1 (ru) | Dpp3 для осуществления, мониторинга и стратификации терапии nt-adm антителами у пациентов с шоком | |
| RU2855130C2 (ru) | Антитело против адреномедуллина (adm), или фрагмент антитела против adm, или анти-adm не-ig каркас для применения в терапии или профилактике шока | |
| WO2024023369A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock | |
| CA3207969A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock and prediction of an increase of dpp3 in a critically ill patient | |
| RU2854796C1 (ru) | Связующее вещество против адреномедуллина (adm) для применения в терапии пациентов в состоянии шока | |
| US20230250166A1 (en) | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock | |
| EP4687942A1 (en) | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220822 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250218 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250218 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250704 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260212 |